We can’t show the full text here under this license. Use the link below to read it at the source.
Comparative effectiveness of sodium‐glucose cotransporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists for incident dementia: A retrospective multicohort study
Comparing SGLT2 inhibitors and GLP-1 receptor agonists for new cases of dementia
AI simplified
Abstract
Among 32,542 adults with type 2 diabetes, 581 using GLP-1 receptor agonists and 572 using SGLT2 inhibitors developed dementia during a median 6.3-year follow-up.
- No significant differences in the risk of all-cause dementia were found between users of GLP-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors.
- The hazard ratio for all-cause dementia was 1.01, indicating a similar risk for both medication groups.
- Subgroup analyses supported the absence of significant differences in the incidence of vascular and Alzheimer's dementia.
- SGLT2 inhibitor use was not associated with an increased risk of dementia compared to GLP-1 receptor agonists.
AI simplified